{{Drugbox
| IUPAC_name = ''N''-1-naphthalenyl-1-pentyl-1''H''-indole-3-carboxamide
| image = NNEI_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1338925-11-3
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 54752945
| ChemSpiderID      = 26613275
| smiles            = CCCCCn1cc(c2c1cccc2)C(=O)Nc1cccc2c1cccc2
| StdInChI          = 1S/C24H24N2O/c1-2-3-8-16-26-17-21(20-13-6-7-15-23(20)26)24(27)25-22-14-9-11-18-10-4-5-12-19(18)22/h4-7,9-15,17H,2-3,8,16H2,1H3,(H,25,27)
| StdInChIKey       = GWCQNKRMTGVYIZ-UHFFFAOYSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7FVT9P642K

<!--Chemical data-->
| C=24 | H=24 | N=2 | O=1
| molecular_weight = 356.47 g/mol
}}

'''NNE1''' (also known as '''NNEI''', '''MN-24''' and '''AM-6527''') is an [[indole]]-based [[synthetic cannabinoid]], representing a [[molecular hybrid]] of [[APICA (synthetic cannabinoid drug)|APICA]] and [[JWH-018]].<ref>{{cite journal | url=http://www.fsijournal.org/article/S0379-0738%2814%2900115-7/abstract | title=Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products | author=Nahoko Uchiyama| journal=Forensic Science International |date=October 2014  | volume=243 | pages=1–13 | doi=10.1016/j.forsciint.2014.03.013 | pmid=24769262|display-authors=etal}}</ref> It was invented by [[Abbott Laboratories|Abbott]] and has a [[CB1 receptor|CB<sub>1</sub> receptor]] pEC<sub>50</sub> of 8.9 (i.e. EC<sub>50</sub> of approximately 1nM) with around 80x selectivity over the related [[CB2 receptor|CB<sub>2</sub> receptor]].<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S022352341100612X | title=Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity | author=Antoni R. Blaazer| journal=European Journal of Medicinal Chemistry |date=October 2011  | volume=46 | issue=10 | pages=5086–5098 | doi=10.1016/j.ejmech.2011.08.021 | pmid=21885167|display-authors=etal}}</ref> It is suspected that metabolic hydrolysis of the amide group of NNE1 may release [[1-naphthylamine]], a known [[carcinogen]], given the known metabolic liberation (and presence as an impurity) of [[amantadine]] in the related compound [[APINACA]], and NNE1 was banned in New Zealand in 2012 as a [[temporary class drug]] to stop it being used as an ingredient in then-legal [[synthetic cannabis]] products.<ref>[https://gazette.govt.nz/notice/id/2012-go7051 New Zealand Government Gazette, Notice Number 7051, 1 November 2012]</ref> NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.<ref>{{cite journal | url=https://link.springer.com/article/10.1007%2Fs11419-014-0246-5 | title=A case of death caused by abuse of a synthetic cannabinoid N -1-naphthalenyl-1-pentyl-1H -indole-3-carboxamide | author=Chizuko Sasaki| journal=Forensic Toxicology |date=January 2015  | volume=33 | issue=1 | pages=165-169 | doi=10.1007/s11419-014-0246-5|display-authors=etal}}</ref>

==See also==
* [[5F-NNE1]]
* [[5F-PCN]]
* [[AM-2201]]
* [[APICA (synthetic cannabinoid drug)|APICA]]
* [[CUMYL-PICA]]
* [[FDU-NNE1]]
* [[JWH-018]]
* [[NM-2201]]
* [[SDB-005]]

==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Naphthoylindoles]]
[[Category:Indolecarboxamides]]

{{cannabinoid-stub}}